<DOC>
	<DOCNO>NCT00127777</DOCNO>
	<brief_summary>This randomize , multi-center , partially placebo-controlled Phase IV study compare efficacy tolerability 48-week combined therapy pegylated interferon alpha-2a , ribavirin amantadine sulphate versus placebo untreated patient chronic hepatitis C virus-genotype-1-infection . The hypothesis increase sustain response rate triple therapy compare current standard treatment .</brief_summary>
	<brief_title>Peginterferon Alfa-2a , Ribavirin , Amantadine/Placebo Hepatitis C Virus ( HCV ) -Genotype-1-Infection ( PRAMA )</brief_title>
	<detailed_description>Primary Objective : - Proof triple-therapy ( peginterferon alfa-2a , ribavirin amantadine sulphate ) dispense period 50 week , improve permanent virological efficacy 10 % compare combination therapy peginterferon alpha-2a ribavirin , define negative HCV-RNA result obtain molecular verification method ( e.g . Roche AmplicorTM HCV , v.2.0 , sensitivity &lt; 50 IE/ml ) 24 week end therapy . Secondary Objectives : - Verification initial virological efficacy week 12 , define negative HCV-RNA test result mean quantitative proof method , e.g . Roche AmplicorTM HCV Monitor v.2.0 ( sensitivity &lt; 600 IE/ml ) . - Biochemical efficacy , define serum GPT value 24 week end therapy . - Virological efficacy , measure basis HCV-RNA value end therapy . - Biochemical efficacy define serum GPT value end therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Female male subject 18 year age 70 year age Serological indication chronic hepatitis C infection positive antiHCV test serum HCVRNA quantification &gt; 600 IE/ml mean quantitative proof method , e.g . Roche AmplicorTM HCV Monitor test , v.2.0 . Untreated patient HCVinduced chronic infection . Indication genotype HCV1 basis reverse hybridize assay Inno LiPA Bayer Versant ( Innogenetics ) . Increased GPT serum level least one determination date within 56day screen phase prior start administration study medication . Histological identification inflammatory activity liver , without indication compensate cirrhosis , 24 month prior start study . Compensated liver disease ( ChildPugh Grade A ) . Negative urine serum pregnancy test fertile female subject within 24 hour take first dose study medication . During administration study medication 24 week treatment stop , patient must apply two approved contraception method , one must barrier effect male , e.g . condom . If one inclusion criterion fulfil , patient exclude study ! Any known sensitive reaction interferon , ribavirin amantadine sulphate . Pregnant breastfeed woman fertile woman practice contraception . Male partner pregnant woman . Previous treatment interferon and/or ribavirin . Treatment systemic antineoplastic immunomodulatory medication ( supraphysiologic dos steroid radiation include ) within last 6 month prior study throughout whole study . Immunosuppressed/immunocompromised patient . Participation clinical study within last three month . Infection HCV genotype2 , 3 , 4 , 5 6 . Positive indication HBsAg , HIV antibodies screen phase . Nonhepatitis C virusinduced chronic hepatitis ( e.g . hematochromatosis , autoimmune hepatitis , metabolic alcoholic liver disease ) . Decompensated liver cirrhosis liver disease ; ChildPugh Grade B C ; threshold compensate liver disease . Signs hepatocellular carcinoma within 2 month randomization , couple exist develop cirrhosis . History oesophagus varix haemorrhage . Hemoglobin &lt; 12 g/dl female subject &lt; 13 g/dl male subject screen phase . Subjects high risk anemia ( e.g . thalassemia , spherocytosis , history gastrointestinal bleeding ) subject anemia could highly potential medical risk . Neutropenia &lt; 1500 /µl thrombocytopenia &lt; 90,000 /µl diagnose screen phase . Serum creatinine &gt; 1.5 mg/dl screen phase . History severe psychiatric disease , especially severe depression , whereby severe psychiatric disease define antidepressive antipsychotic therapy least 3 month history , indication suicidal inclination hospitalization cause psychiatric disease . Epilepsy . Autoimmune disease ( e.g . inflammatory intestinal disease , idiopathic thrombocytopenic purpura , lupus erythematosus sclerodermia , severe psoriasis , rheumatoid arthritis , etc. ) . History thyroid disease , poorly control prescribed medication Chronic pulmonary disease functional restriction . History severe cardiac disease , e.g . cardiac insufficiency New York Heart Association ( NYHA ) class III IV ; myocardial infarction within last 6 month ; ventricular tachyarrhythmia require treatment ; unstable angina pectoris ; cerebrovascular circulation disorder ; significant cardiovascular disease . Patients pacemaker . Cardiomyopathy myocarditis Atrioventricular ( AV ) block Grade II III . Previously know bradycardia rating 55 strokes/minute Known , lengthy QTinterval ( QTc per Bazett &gt; 420 m ) recognizable U wave hereditary QTsyndrome family history . History severe ventricular arrythmia include Torsade de pointes . Simultaneous therapy budipine QTextending medication : Certain antiarrhythmias class IA ( e.g . quinidine , disopyramide , procainamide ) class III ( amiodarone , sotalol ) ; Certain antipsychotic ( e.g . thioridazine , chlorpromazine , haloperidol , pimozide ) ; Certain tri tetracyclic antidepressive medication ( e.g . amitriptyline ) ; Certain antihistaminic medication ( e.g . astemizol , terfenadin ) ; Certain macrolide antibiotic ( e.g . erythromycin , clarithromycin ) ; Certain gyrase inhibitor ( e.g . sparfloxacin ) ; Azoleantimycotics medication halofantrine , cotrimoxazol , pentamidine , cisapride bepridil ; Simultaneous treatment Memantine . Morbus Parkinson . History major organ transplantation , exception cornea transplantation . Cancer disease , , opinion investigator , exclusion criterion study . Evidence severe retinopathy ( e.g . cytomegalovirus [ CMV ] retinitis macular degeneration ) . Patients narrowangle glaucoma . Active drug abuse ( excessive alcohol consumption include ) within last year prior study ( exception prescribe substitute ) . Patients state agitation confusion Patients history acute brain syndrome exogenous psychosis Patients already enrol study . Prostate hypertrophy Simultaneous administer diuretic combination type triamterene/hydrochlorothiazide . Unwillingness incapability give write consent receive medical information ; doubt proper protection patient data ; general reluctance take part study adhere study term . If one exclusion criterion fulfil , patient shall exclude study !</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>HCV genotype 1</keyword>
	<keyword>peginterferon alfa-2a</keyword>
	<keyword>ribavirin</keyword>
	<keyword>amantadine</keyword>
	<keyword>treatment-naive</keyword>
</DOC>